The Validity and Reliability of the Turkish Version of the CPAQ-8

February 25, 2022 updated by: Ahmet Kivanc Menekseoglu, Istanbul University

The Validity and Reliability of the Turkish Version of the Chronic Pain Acceptance Questionnaire-8

Acceptance of chronic pain is becoming an increasingly important issue in the field of pain management. Many researchers argue that patients who accept pain better function better both physically and psychologically. In many countries, the Chronic Pain Acceptance Questionnaire - 8 (CPAQ-8) has been frequently validated and used to measure the pain acceptance of patients with chronic pain.1 However, the CPAQ-8 has not yet been introduced and validated in Turkey. In this study, we aimed to translate the English version of CPAQ-8 into Turkish, make correct cross-cultural adaptations, and validate the psychometric properties of the Turkish version of CPAQ-8 by testing it in Turkish fibromyalgia patients.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Chronic pain is an undesirable condition that affects a large part of the society and increases the psychological and economic burden of the population it affects. Psychological variables are known to be strong in the perception of pain and especially cause patients to avoid activity in order to reduce pain. Individuals prefer to avoid painful experiences when they are worn out in repetitive attempts to control and prevent pain, which ultimately causes pain to become more dominant and destructive, and activities that are valuable to the individual are neglected.1 At this point, accepting pain can be seen as the antithesis of avoiding painful experiences. Acceptance of pain is a strong predictor of low disability in chronic pain.2 The Chronic Pain Acceptance Questionnaire (CPAQ) represents one of the ways in which pain acceptance is functionalized and measured in the context of chronic pain. The short form of CPAQ, CPAQ-8, was developed and validated recently and shows the same factor structure, reliability and validity as the 20-factor version. Given that psychometric testing is an incremental process, further evaluation of the questionnaire is desirable, including test-retest reliability and replication of results reported by Fish et al.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
80

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • Istanbul, Turkey, 34015
        • Ahmet Kıvanç Menekşeoğlu

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Patients who applied to our physical medicine and rehabilitation outpatient clinic, agreed to participate in the study, were over the age of 18, had at least primary school education, were diagnosed with fibromyalgia syndrome according to the 2016 American College of Rheumatology (ACR) criteria, and could speak and communicate in Turkish were included in the study.

Description

Inclusion Criteria:

  • Patients who applied to our physical medicine and rehabilitation outpatient clinic,
  • Agreed to participate in the study, were over the age of 18,
  • Had at least primary school education, were diagnosed with fibromyalgia syndrome according to the 2016 American College of Rheumatology (ACR) criteria,
  • Could speak and communicate in Turkish were included in the study.

Exclusion Criteria:

  • Those who did not agree to participate in the study,
  • <18 years old, and could not communicate in Turkish

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Fibromyalgia Impact Questionnaire
Time Frame: 01.01.2020-31.12.2021
The Fibromyalgia Impact Questionnaire was used to measure patients' symptom severity and functional status. There are 10 items in the FIQ; each item gets a score between 0-10. The first item questions the ability to perform activities of daily living with 11 questions. Other items question general well-being, ability to work, and symptoms of pain, fatigue, stiffness, anxiety, and depression. The score range is 0 to 100; higher scores indicate severe disease.
01.01.2020-31.12.2021

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Hospital Anxiety and Depression Scale
Time Frame: 01.01.2020-31.12.2021
Hospital Anxiety and Depression Scale (HADS) consists of 14 items. It is designed to assess the severity of anxiety and depression in patients.Each item is scored between 0-3; higher scores indicate more anxiety or depression.
01.01.2020-31.12.2021
Tampa Scale of Kinesiophobia
Time Frame: 01.01.2020-31.12.2021
Tampa Scale of Kinesiophobia (TSK) is a 17 item self-reporting questionnaire based on evaluation of fear of movement, fear of physical activity, and fear avoidance. . Scoring ranges from 1 to 4 points for each item, with higher scores indicating greater fear of injury.
01.01.2020-31.12.2021
Brief Pain Inventory
Time Frame: 01.01.2020-31.12.2021
Brief Pain Inventory consists of four questions about the severity of pain and seven questions about its effect on daily functions. The inventory assesses an individual's walking, exercise, sleep, emotional state, general activity status, social relations, and joy in the last 24 hours. Each item gets scored between 0 and 10, ; higher scores indicate severe disease.
01.01.2020-31.12.2021

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Istanbul University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 1, 2020

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
January 1, 2020

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 31, 2021

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
February 12, 2022

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 12, 2022

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
February 23, 2022

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 14, 2022

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 25, 2022

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
February 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 2019/58

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings